Bacterin Announces Third Quarter 2014 Results Third

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Bacterin Announces Third Quarter 2014 Results

Third Quarter Highlights:

  • Third Quarter 2014 total revenue increased approximately 6.6% to $8.454 million from $7.930 million reported during the third quarter of 2013
  • Gross profit increased 17.9% to $5.436 million compared to $4.612 million reported during the third quarter of 2013
  • Gross margins improved to 64.3%, an increase from 58.2% reported in the third quarter of 2013
  • Net loss from operations decreased to a loss of $1.250 million, a significant improvement compared to a loss of $2.347 million during the third quarter of 2013.

BELGRADE, Mont., Nov. 5, 2014 (GLOBE NEWSWIRE) -- Bacterin International Holdings, Inc. (NYSE MKT:BONE), a leader in the development of bone graft material and coatings for medical applications, today reported financial results for the third quarter ended September 30, 2014.

Revenue

Third quarter 2014 revenues were $8.454 million, an increase of 6.6% over third quarter 2013 revenues of $7.930 million. The higher revenues reflect the company's ongoing investment in its hybrid sales function calling on orthopedic surgeons and neurosurgeons.

"We continue to deliver solid, organic, year-over-year growth," said Dan Goldberger, CEO of Bacterin International. "Our tenured sales representatives are becoming more productive and we are more effectively recruiting experienced sales talent as well as increasing the number of manufacturer representatives carrying Bacterin products."

Gross Profit

Gross profit reported for the third quarter of 2014 increased 17.9% to $5.436 million from $4.612 million reported for the third quarter of 2013. The higher gross profit was due to sales mix and ongoing productivity improvements.

Gross margins for the period were 64.3%, an increase over the Company's 2013 third quarter reported gross margin of approximately 58.2%. Although the Company's reported margins were in excess of 63%, the Company reiterated its guidance on gross margins within the previously announced range of 61.0% to 63.0%.

Sales and Marketing Expenses

Third quarter 2014 sales and marketing expenses decreased 3.1% to $3.927 million, as compared to $4.054 million during the same period in 2013. Sales and marketing as a percentage of revenues decreased to 46.5%, which compares favorably to 51.1% reported for the third quarter of 2013.

General and Administrative Expenses

General and administrative expenses for the quarter decreased 16.3% to $2.282 million, compared to $2.727 million reported during the third quarter of 2013.

Research and Development Expenses

The Company reported third quarter 2014 research and development expenses of approximately $378,000 related to its ongoing product development initiatives.

Loss from Operations

The reported third quarter 2014 loss from operations was $1.250 million, a 46.7% decrease from the year-ago period operating loss of $2.347 million. "We continue to demonstrate strong financial discipline in our organization as evidenced by our increasing gross margin and decreasing operating loss," said Dan Goldberger, CEO of Bacterin International.

EBITDA

The Company defines earnings before interest, taxes, depreciation and amortization ("EBITDA") as net income/loss from operations before depreciation, amortization and non-cash stock-based compensation. EBITDA for the third quarter of 2014 was a loss of approximately $839,000, a significant improvement over the third quarter of 2013 EBITDA loss of $1.847 million.

Financial Liquidity

As of September 30, 2014 the Company had cash and cash equivalents of approximately $6.953 million, which compares to $3.046 million as of December 31, 2013.

Call Details

The Company will hold a conference call hosted by Dan Goldberger, Chief Executive Officer, and John Gandolfo, Chief Financial Officer, to discuss financial results at 10:00 a.m. ET, on Thursday, November 6, 2014. Please refer to the information below for conference call dial-in information and webcast registration.

Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact the Cockrell Group at 1-877-889-1972.

Conference date: November 6, 2014, 10:00 AM ET

Conference dial-in: 877-269-7756

International dial-in: 201-689-7817

Conference Call Name: Bacterin's Third Quarter 2014 Results Call

Webcast Registration: Click Here

Following the live call, a replay will be available on the Company's website, www.bacterin.com , under "Investor Info".

About the Presentation of EBITDA

EBITDA is not a financial measure calculated and presented in accordance with U.S. generally accepted accounting principles (GAAP) and should not be considered as an alternative to net income, operating income or any other financial measures so calculated and presented, nor as an alternative to cash flow from operating activities as a measure of liquidity. The company defines EBITDA as net income/(loss) from operations before depreciation, amortization and non-cash stock-based compensation. Other companies (including competitors) may define EBITDA differently. The company presents EBITDA because management believes it to be an important supplemental measure of performance that is commonly used by securities analysts, investors and other interested parties in the evaluation of companies in our industry. Management also uses this information internally for forecasting and budgeting. It may not be indicative of the historical operating results of Bacterin nor is it intended to be predictive of potential future results. Investors should not consider EBITDA in isolation or as a substitute for analysis of the company's results as reported under GAAP.

About Bacterin International Holdings

Bacterin International Holdings, Inc. (NYSE MKT:BONE) develops, manufactures and markets biologics products to domestic and international markets. These products are used in a variety of applications including enhancing fusion in spine surgery, relief of back pain, promotion of bone growth in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral repair in knee and other joint surgeries.

Bacterin's Medical Device division develops, employs, and licenses coatings for various medical device applications. For further information, please visit www.bacterin.com .

Important Cautions Regarding Forward-looking Statements

This news release contains certain disclosures that may be deemed forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to significant risks and uncertainties. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as "continue," "efforts," "expects," "anticipates," "intends," "plans," "believes," "estimates," "projects," "forecasts," "strategy," "will," "goal," "target," "prospects," "potential," "optimistic," "confident," "likely," "probable" or similar expressions or the negative thereof. Statements of historical fact also may be deemed to be forward-looking statements. We caution that these statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the Company's ability to meet its existing and anticipated contractual obligations, including financial covenant and other obligations contained in the Company's secured lending facility; the Company's ability to manage cash flow and achieve profitability; the Company's ability to remain listed on the NYSE MKT; the Company's ability to develop, market, sell and distribute desirable applications, products and services and to protect its intellectual property; the ability of the Company's sales force to achieve expected results; the ability of the Company's customers to pay and the timeliness of such payments; the Company's ability to obtain financing as and when needed; changes in consumer demands and preferences; the Company's ability to attract and retain management and employees with appropriate skills and expertise; the Company's ability to successfully conclude government investigations; the impact of changes in market, legal and regulatory conditions and in the applicable business environment, including actions of competitors; and other factors. Additional risk factors are listed in the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q under the heading "Risk Factors." The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.

     
BACTERIN INTERNATIONAL HOLDINGS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
  As of  
  September 30, As of
  2014 December 31,
  (Unaudited) 2013
     
ASSETS    
Current Assets:    
Cash and cash equivalents $ 6,953,279 $ 3,046,340
Trade accounts receivable, net of allowance for doubtful accounts of $1,463,046 and $1,309,859, respectively 4,294,496 4,793,834
Inventories, net 11,139,471 10,753,600
Prepaid and other current assets 808,213 574,910
Total current assets 23,195,459 19,168,684
     
Non-current inventories 1,635,380 2,119,952
Property and equipment, net 4,767,137 5,180,556
Intangible assets, net 649,119 586,965
Other assets 1,566,059 1,821,471
     
Total Assets $ 31,813,154 $ 28,877,628
     
LIABILITIES & STOCKHOLDERS' (DEFICIT) EQUITY    
Current Liabilities:    
Accounts payable $ 3,893,250 $ 2,767,639
Accounts payable - related party 406,669 647,844
Accrued liabilities 1,947,328 3,585,037
Warrant derivative liability 2,018,234 1,594,628
Current portion of capital lease obligations 109,235 171,926
Current portion of royalty liability 951,500 836,750
Current portion of long-term debt 49,918 47,727
Total current liabilities 9,376,134 9,651,551
     
Long-term Liabilities:    
Capital lease obligation, less current portion 9,782 73,777
Long term royalty liability, less current portion 6,425,500 6,609,232
Long-term debt, less current portion 20,459,494 16,385,245
Total Liabilities 36,270,910 32,719,805
     
Commitments and Contingencies    
Stockholders' (Deficit) Equity    
Preferred stock, $.000001 par value; 5,000,000 shares authorized; no shares issued and    
outstanding -00 -00
Common stock, $.000001 par value; 95,000,000 shares authorized; 6,684,551 shares issued and outstanding as of September 30, 2014 and 5,343,282 shares issued and outstanding as of December 31, 2013 7 5
Additional paid-in capital 63,107,378 56,516,491
Accumulated deficit (67,565,141) (60,358,673)
Total Stockholders' (Deficit) Equity (4,457,756) (3,842,177)
     
Total Liabilities & Stockholders' (Deficit) Equity $ 31,813,154 $ 28,877,628
     
On July 25, 2014, the Company completed a 1:10 reverse split of its common stock, effective at the close of business on Friday, July 25, 2014 and in effect for trading purposes on Monday, July 28, 2014. All references to common shares and per share amounts have been retroactively adjusted to reflect the stock split for all periods presented.
     
     
 
BACTERIN INTERNATIONAL HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
 
  Three Months Ended September 30, Nine Months Ended September 30,
  2014 2013 2014 2013
Revenue        
Tissue sales $ 8,246,325 $ 7,710,256 $ 25,712,586 $ 24,430,158
Royalties and other 207,179 219,727 537,821 385,480
Total Revenue 8,453,504 7,929,983 26,250,407 24,815,638
         
Cost of tissue and medical devices sales 3,017,734 3,318,327 9,718,952 10,011,687
         
Gross Profit 5,435,770 4,611,656 16,531,455 14,803,951
  64.3% 58.2% 63.0% 59.7%
Operating Expenses        
General and administrative 2,282,386 2,726,586 6,664,982 7,652,958
Sales and marketing 3,927,028 4,053,679 12,387,459 12,057,389
Research and development 378,252 37,742 955,111 224,739
Depreciation and amortization 58,763 97,923 216,343 304,771
Non-cash consulting expense 39,697 43,153 81,924 11,924
Total Operating Expenses 6,686,126 6,959,083 20,305,819 20,251,781
         
Loss from Operations (1,250,356) (2,347,427) (3,774,364) (5,447,830)
         
Other Income (Expense)        
Interest expense (1,498,508) (1,197,370) (4,216,109) (3,436,006)
Change in warrant derivative liability 1,653,425 (849,288) 1,038,190 246,337
Other income (expense) (70,344) 17,551 (253,289) 108,616
         
Total Other Income (Expense) 84,573 (2,029,107) (3,431,208) (3,081,053)
         
Net Loss $ (1,165,783) $ (4,376,534) $ (7,205,572) $ (8,528,883)
         
Net loss per share:        
Basic $ (0.19) $ (0.85) $ (1.26) $ (1.83)
Dilutive $ (0.19) $ (0.85) $ (1.26) $ (1.83)
         
Shares used in the computation:        
Basic 6,233,751 5,161,631 5,711,452 4,661,135
Dilutive 6,233,751 5,161,631 5,711,452 4,661,135
 
On July 25, 2014, the Company completed a 1:10 reverse split of its common stock, effective at the close of business on Friday, July 25, 2014 and in effect for trading purposes on Monday, July 28, 2014. All references to common shares and per share amounts have been retroactively adjusted to reflect the stock split for all periods presented. 
 
BACTERIN INTERNATIONAL HOLDINGS, INC.
RECONCILIATION OF EARNINGS BEFORE INTEREST, TAXES,
DEPRECIATION AND AMORTIZATION (EBITDA)
(Unaudited)
 
  Three Months Ended
  September 30,
  2014 2013
EBITDA    
Net loss from operations $ (1,250,356) $ (2,347,427)
Depreciation and amortization 58,763 97,923
Allocated depreciation 94,000 94,000
Stock option compensation 218,675 265,607
Non-cash consulting expense 39,697 43,153
  $ (839,221) $ (1,846,744)
 

Investor Contact: COCKRELL GROUP Rich Cockrell 877-889-1972 cockrellgroup.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Katahdin's Portland Branch Bet Moves Downtown in 2027

Updated Category News Views 61

Exchange Street is getting a real-world vote of confidence, and that is more interesting than another app update ever will be. Katahdin Trust intends to open a full-service branch at 120 Exchange Street in downtown Portland, with renovations slated to begin early in 2027 and an opening expected later that year. For a Maine community bank with nearly $1.2 billion in...

Continue Reading
Washington-to-Asia Advisory Deal Targets Policy Risk

Updated Category News Views 10

Policy bottlenecks are becoming a cost center across Southeast Asia. That is the plain-English backdrop for the strategic partnership announced November 18, 2026, by Beacon Global Strategies and Vriens & Partners. Neither firm is selling a factory, a chip design, or a new energy project. They are selling something companies increasingly cannot afford to improvise: a...

Continue Reading
APEC's Shared-Prosperity Message Needs More Detail

Updated Category News Views 20

Geese make handsome symbols, but markets cannot underwrite a metaphor. The Nov. 18, 2026 report from Xinhua News Agency looks back to remarks Chinese President Xi Jinping made 12 years ago, when he used swan geese to urge APEC economies toward greater cooperation and a new collective flight. Its present-day message is plainly hopeful: the APEC family is moving across the...

Continue Reading
CVRx Lawsuit Deadline Follows a Brutal 59.76% Plunge

Updated Category News Views 24

A 59.76% one-day wipeout has a way of stripping the varnish off every upbeat corporate story. For CVRx investors, the hard fact is that the shares fell $3.55 to close at $2.39 on August 7, 2026, after the company disclosed a U.S. Department of Justice civil investigative demand in its August 6 Form 10-Q. That kind of disclosure does not merely dent confidence; it forces...

Continue Reading
Haemonetics Opens Europe for VASCADE MVP XL Device

Updated Category News Views 31

A larger collagen plug is hardly cocktail-party material, yet it can matter a great deal when it sits inside a procedure workflow hospitals are trying to speed up. Haemonetics has received CE Mark certification under the EU Medical Device Regulation for VASCADE MVP XL, its larger-bore venous vascular closure system, and first commercial European procedures were completed...

Continue Reading
Fapon’s Enzyme Push Meets Diagnostics Reality at AMP

Updated Category News Views 85

Enzymes rarely get applause at industry meetings, but they can quietly decide whether a diagnostic workflow behaves or becomes a lab headache. Fapon used its AMP 2026 appearance in Seattle to make that unglamorous case: better enzyme design may help assays move faster and keep working when samples get messy. The company wrapped up the November 10–14 meeting after...

Continue Reading
Photocure Opens a New Access Route for Hexvix Patients

Updated Category News Views 31

Forty-plus markets just moved from “not available” toward a workable route for individual bladder cancer patients, and that is the real substance of Photocure’s new arrangement with Clinigen. This is not a sweeping product launch, nor is it an approval announcement dressed up in confetti. It is a Named Patient Program, which matters because the regulatory plumbing...

Continue Reading
Kids First Data Sharing Raises Pediatric Research Bar

Updated Category News Views 68

Thirty-eight thousand children’s records are not a headline gimmick; they are a serious argument for treating research data as an asset that must keep working after the first study ends. The Gabriella Miller Kids First Data Resource Center’s ten-year review, published in the September 2026 issue of The American Journal of Human Genetics, makes that argument with...

Continue Reading
DEFSEC Tackles Nasdaq Bid Price Hurdle with Share Move

Updated Category News Views 68

Navigating Bid Price Deficiency Issues Well, it seems DEFSEC Technologies Inc. found themselves in a tricky spot last week. A nasty gram from Nasdaq’s Listing Qualifications Department pointing out that DEFSEC's shares had dipped below that $1.00 per share requirement for too long—a full 30 business days. Now, don't panic just yet. This isn't about the shares getting...

Continue Reading
WYBOT's New Robots Push Hands-Free Pool Care in Lyon

Updated Category News Views 0

A pool robot climbing out of the water to dock itself is the sort of demo that makes people stop mid-aisle at a trade show. WYBOT brought precisely that kind of attention-grabber to Piscine Global Lyon 2026, running November 17–20 at Eurexpo Lyon. The company is showing a broader lineup, but the M3 Pro is plainly the headline act: WYBOT calls it the world's first...

Continue Reading

Top 5 Most Recently Viewed Articles

Michael Baker International Enhances Pavement Management Strategies

Updated Category News Views 313

Michael Baker International Teams Up with CVAG Michael Baker International, a well-known leader in engineering and consulting services, has recently been selected by the Coachella Valley Association of Governments (CVAG) for an important project focused on improving the area's pavement condition assessments. This partnership marks a significant step toward enhancing the...

Continue Reading
Fidus Investment Corporation Announces $100 Million Note Offering

Updated Category News Views 307

Fidus Investment Corporation's Recent Offering Announcement Fidus Investment Corporation (NASDAQ: FDUS) has recently made a significant announcement regarding its financial strategy. The company has priced an underwritten public offering of 6.750% notes, with an aggregate principal amount of $100 million, due in 2030. This initiative is aimed at strengthening its capital...

Continue Reading
WillScot Strengthens Board with New Appointment to Drive Growth

Updated Category News Views 49

WillScot Appoints Worthing Jackman to Board of Directors WillScot Holdings Corporation (NASDAQ: WSC), a leader in flexible space and storage solutions, has made a strategic move by appointing Worthing Jackman to its Board of Directors. This significant addition is aimed at reinforcing the company's growth strategy and bolstering its financial and operational performance....

Continue Reading
National Press Club Reacts to Pentagon's New Media Restrictions

Updated Category News Views 510

Concerns Regarding Pentagon's Media Access Restrictions Recently, the National Press Club leadership voiced significant concerns about new media restrictions imposed by the Pentagon. A statement from the club highlighted that these restrictions threaten transparency and reduce public access to information critical for accountability. Impact on Journalistic Integrity...

Continue Reading
Dogecoin and Shiba Inu Surge: A New Era for Meme Coins

Updated Category News Views 100

A Look at the Recent Surge in Dogecoin and Shiba Inu Recently, Dogecoin and Shiba Inu, both leaders in the meme coin market, have experienced notable price spikes. Dogecoin's value has risen by 4.5%, while Shiba Inu has jumped an impressive 8%. These increases follow important economic news about a cut in interest rates, which is bringing renewed optimism among crypto...

Continue Reading